Good Morning Market Enthusiast,
 

We’ve been working non-stop to deliver back-to-back-to-back biotech wins, and we’ve just uncovered another one: Alzamend Neuro (Nasdaq: ALZN). This biotech innovator is positioned for some potentially big moves. (3)(5)

(6)

Here’s why Alzamend Neuro (Nasdaq: ALZN) deserves your attention:
 

🧪 Breakthrough Science

Alzamend has teamed up with Massachusetts General Hospital to run five Phase II clinical trials targeting critical conditions like Alzheimer’s, bipolar disorder (BD), major depressive disorder (MDD), and PTSD—which affect over 43 million Americans. (1)(6)(7)(8)
 

💡 Their lead candidate, AL001, aims to deliver the benefits of lithium therapy while avoiding its common side effects, with a 20% lower daily dosage. This could change how lithium is used in treatment, offering a safer alternative for patients suffering from Alzheimer’s, BD, MDD, and PTSD. (1)(6)(7)
 

The exciting part is that AL001 has shown great promise in clinical trials so far. The results have demonstrated that it could provide better safety for patients with fewer risks associated with traditional lithium treatments. For example, it reduces the need for regular blood monitoring, a significant advantage for patients undergoing long-term care. With its potential to disrupt the lithium market, AL001 is drawing a lot of attention as it moves one step closer to approval. (1)(6)(7)
 

🧬 Revolutionizing Alzheimer’s Treatment

Their second candidate, ALZN002, takes a novel approach to Alzheimer’s, activating the body’s immune system to fight the disease by targeting and removing harmful brain plaques. This could lead to long-lasting effects and improved quality of life for patients suffering from this devastating condition. Current Alzheimer’s treatments provide limited relief, and ALZN002 could be the breakthrough patients and families have been waiting for. (1)(6)(7)

The company’s active immunotherapy approach with ALZN002 is particularly interesting. Unlike many treatments that only slow the progression of Alzheimer’s, ALZN002 has the potential to train the body’s immune system to actively fight the disease. This innovative strategy could revolutionize the way Alzheimer’s is treated, offering patients hope for long-term improvement rather than temporary relief. (1)(6)(7)

(7)

🛫 Big Movement Potential

With only around 4 million shares available, Alzamend Neuro (Nasdaq: ALZN) is primed for significant movements. Companies like this can see rapid gains with increased trading volume, offering potential for big price action. If trading volume picks up as more people support the progress being made with AL001 and ALZN002, the company could experience substantial upward momentum.
 

💼 Financially Backed for Growth

Alzamend has secured 18 months of capital to fuel their clinical trials, ensuring continuous progress without financial hurdles. This funding not only covers the trials for AL001 and ALZN002 but also allows for strategic advancements in other areas of the company. With the solid backing in place, Alzamend is well-positioned to push these clinical trials through to the next stages. (1)(6)(7)
 

🚨 The Bottom Line:
 

We’ve delivered back-to-back biotech wins, and Alzamend Neuro (Nasdaq: ALZN) could be the next big one to watch. With groundbreaking clinical trials, innovative treatments, and strong financial support, this company is poised for something major.

Check out Alzamend Neuro (Nasdaq: ALZN) now!

To Your Success,

Max Masters

Co-founder, Market Tips Newsletter

Sources:
1. https://bit.ly/3U36lwq
2. https://alzamend.com/
3. https://finance.yahoo.com/quote/ALZN/
4. https://yhoo.it/3BBCViO
5. https://yhoo.it/3U5BbVk
6. https://yhoo.it/4eE99bN 
7. https://bit.ly/3U6ptcT
8. https://on.mktw.net/3Y09tdM

Data is provided from third-party sources and Market Tips is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized fin.ancial advice, are not finan.cial advisors, and our opinions are not suitable for all in.vest.ors. Please review our full disc.laim.er here. 

Pursuant to an agreement between Momentum Media LLC and LFG Equities, Momentum Media LLC has been hired for a period beginning on 10/15/2024 and ending on 10/16/2024 to publicly disseminate information about (ALZN:US) via digital communications. To date we have been paid twenty two thousand five hundred dollars USD. We own zero shares of (ALZN:US).